OncoMatch/Clinical Trials/NCT06766916
Crisugabalin for Radiotherapy-Related Neuropathic Pain
Is NCT06766916 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Crisugabalin and Pregabalin for neuropathic pain.
Treatment: Crisugabalin · Pregabalin — The purpose of this study is to evaluate whether Crisugabalin has similar efficacy compared to Pregabalin in reducing radiotherapy-related neuropathic pain (RRNP) in patients with head and neck cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Must have received: radiotherapy
head and neck tumors treated with radiotherapy at least 6 months prior to screening
Cannot have received: pregabalin
Use of pregabalin/crisugabalin within 4 weeks before screening
Cannot have received: crisugabalin
Use of pregabalin/crisugabalin within 4 weeks before screening
Cannot have received: pregabalin
Previous use of pregabalin ≥300 mg/day deemed ineffective
Cannot have received: gabapentin
Previous use of gabapentin ≥1200 mg/day deemed ineffective
Lab requirements
Blood counts
Neutrophil count <1.5×10⁹/L, platelet count <90×10⁹/L, or hemoglobin <100 g/L excluded
Kidney function
eGFR <60 mL/min/1.73 m² or undergoing dialysis excluded
Liver function
ALT or AST >3× ULN, or TBIL >1.5× ULN excluded
Severe abnormalities in hematological, hepatic, or renal function, as evidenced by: Hematology: Neutrophil count <1.5×10⁹/L, platelet count <90×10⁹/L, or hemoglobin <100 g/L. Liver function: ALT or AST >3× ULN, or TBIL >1.5× ULN. Renal function: eGFR <60 mL/min/1.73 m² or undergoing dialysis. Creatine kinase >2× ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06766916 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pregabalin, crisugabalin, pregabalin disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify